We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

By LabMedica International staff writers
Posted on 28 Aug 2026

Premature ovarian insufficiency (POI) affects up to 3. More...

5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical management more difficult. Beyond its impact on fertility, the condition is associated with risks to bone and cardiovascular health, as well as reduced quality of life. Researchers now show that a single exome-based genetic analysis can identify underlying causes in patients who previously lacked a diagnosis.

At the University of Tartu, investigators evaluated a single exome-based genetic analysis for previously unexplained POI. The approach, detailed in a study published in Human Reproduction Open, was designed to consolidate multiple investigations into one comprehensive test. The study focused on determining whether one analysis could detect several classes of pathogenic genomic variation.

The method uses exome sequencing to analyze the protein-coding regions of the genome. Researchers examined each participant’s exome data for both small-scale variants affecting individual genes and larger abnormalities involving chromosomal regions. By assessing these different variant types simultaneously, the strategy aimed to reduce the likelihood of findings being missed when genetic testing is divided across separate assays.

The cohort included 51 Estonian women with POI for whom routine clinical assessment had not identified an underlying cause. Investigators screened the exome data for pathogenic alterations linked to known genetic causes of the condition. This streamlined approach was designed to provide a more comprehensive assessment of the potential genetic contributors to ovarian dysfunction.

The analysis identified a genetic cause in 12% of participants, representing approximately one in eight women whose condition had remained unexplained following clinical evaluation. The authors noted that many of the genes implicated in these findings are also associated with broader health conditions, suggesting that POI may sometimes represent one feature of a wider clinical picture. 

The authors added that a confirmed genetic diagnosis can guide the assessment of other potential health risks and help determine whether further evaluation or long-term monitoring is needed.

“POI can be caused by a wide variety of genetic changes. In current clinical practice, established genetic causes are often investigated using separate tests, while broader genomic approaches are not yet routinely implemented. As a result, some disease-causing changes may remain undetected. We therefore wanted to determine whether a single exome-based analysis could identify several different types of genetic changes and provide a more comprehensive assessment of the genetic causes of POI,” said Anu Valkna, junior research fellow in human genetics at the University of Tartu.

“A genetic diagnosis of this kind helps us better understand the cause of the condition and can provide important information about whether other family members may also be at risk. It can also support more informed decisions about fertility preservation and family planning,” Valkna emphasized.

Related Links
University of Tartu


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
HPV Test
Allplex HPV28 Detection
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.